Invesco Ltd. Viking Therapeutics, Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 876,222 shares of VKTX stock, worth $46.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

876,222

Previous 707,879 23.78%

Holding current value

$46.1 Million

Previous $37.5 Million 47.83%

% of portfolio

0.01%

Previous 0.01%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$49.84 - $70.47 $8.39 Million - $11.9 Million	168,343 Added 23.78%	876,222 $55.5 Million
Q2 2024 Aug 13, 2024	BUY	$47.39 - $80.2 $566,073 - $957,989	11,945 Added 1.72%	707,879 $37.5 Million
Q1 2024 May 14, 2024	BUY	$17.4 - $94.5 $9.72 Million - $52.8 Million	558,371 Added 405.9%	695,934 $57.1 Million
Q4 2023 Feb 12, 2024	SELL	$9.24 - $19.64 $6.72 Million - $14.3 Million	-727,026 Reduced 84.09%	137,563 $2.56 Million
Q3 2023 Nov 13, 2023	BUY	$10.92 - $16.0 $422,549 - $619,120	38,695 Added 4.69%	864,589 $9.57 Million
Q2 2023 Aug 11, 2023	BUY	$14.84 - $24.79 $12.3 Million - $20.5 Million	825,894 New	825,894 $13.4 Million
Q4 2022 Feb 13, 2023	BUY	$2.72 - $9.4 $702,635 - $2.43 Million	258,322 New	258,322 $2.43 Million
Q2 2022 Aug 15, 2022	SELL	$2.11 - $3.15 $52,144 - $77,845	-24,713 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$3.0 - $4.88 $103,905 - $169,018	-34,635 Reduced 58.36%	24,713 $75,000
Q4 2021 Feb 14, 2022	SELL	$4.6 - $6.72 $20,474 - $29,910	-4,451 Reduced 6.98%	59,348 $273,000
Q3 2021 Nov 15, 2021	BUY	$5.58 - $7.04 $27,263 - $34,397	4,886 Added 8.29%	63,799 $401,000
Q2 2021 Aug 17, 2021	SELL	$5.19 - $6.73 $660,297 - $856,224	-127,225 Reduced 68.35%	58,913 $353,000
Q1 2021 May 17, 2021	BUY	$5.74 - $9.67 $97,557 - $164,351	16,996 Added 10.05%	186,138 $1.18 Million
Q4 2020 Feb 16, 2021	BUY	$5.3 - $6.71 $137,036 - $173,493	25,856 Added 18.05%	169,142 $953,000
Q3 2020 Nov 16, 2020	BUY	$5.73 - $8.11 $5,386 - $7,623	940 Added 0.66%	143,286 $834,000
Q2 2020 Aug 14, 2020	SELL	$4.35 - $8.08 $146,077 - $271,334	-33,581 Reduced 19.09%	142,346 $1.03 Million
Q1 2020 May 15, 2020	BUY	$3.45 - $7.95 $130,682 - $301,138	37,879 Added 27.44%	175,927 $823,000
Q4 2019 Feb 14, 2020	SELL	$6.38 - $8.73 $134,375 - $183,871	-21,062 Reduced 13.24%	138,048 $1.11 Million
Q3 2019 Nov 14, 2019	BUY	$6.55 - $8.6 $183,930 - $241,496	28,081 Added 21.43%	159,110 $1.1 Million
Q2 2019 Aug 14, 2019	BUY	$7.67 - $10.63 $127,114 - $176,170	16,573 Added 14.48%	131,029 $1.09 Million
Q1 2019 May 15, 2019	SELL	$7.58 - $9.94 $118,861 - $155,869	-15,681 Reduced 12.05%	114,456 $1.14 Million
Q4 2018 Feb 14, 2019	BUY	$7.16 - $16.21 $931,780 - $2.11 Million	130,137 New	130,137 $996,000

Others Institutions Holding VKTX

# of Institutions

473

Shares Held

66.2M

Call Options Held

5.72M

Put Options Held

3.39M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.03B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account